Epigenomics AG Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 7/25/2026)
| Balance Sheet | Total Assets | 11,615,000.00 | ROE | 0.02 % |
| Balance Sheet | Total Equity | 2,000.00 | ROA | -2.70 % |
| Cashflow | Capital Expenditures | -1,116.00 | P/FCF | -1.56 |
| Cashflow | Free Cash Flow | -534,116.00 | – | – |
| Cashflow | Operating Cash Flow | -533,000.00 | P/CF | -1.56 |
| Income | Earnings per Share (diluted) | -0.36 | Div. Yield | – |
| Income | Net Income | 2,462,449,000.00 | P/E | -2.64 |
| Income | Shares Outstanding | 876,976.00 | P/B | 416.56 |
| Income | Total Revenue | 24,000.00 | P/S | 34.71 |
Ratios calculated on: 10/14/2026
Company Description
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.epigenomics.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more